quinazolines has been researched along with Dementia Praecox in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (9.09) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 8 (72.73) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chase, KA; Feiner, B; Hu, E; Ramaker, MJ; Rosen, C; Sharma, RP | 1 |
Eda, T; Iwakura, Y; Mizuno, M; Nagata, K; Namba, H; Nawa, H; Okubo, T; Shibuya, M; Sotoyama, H; Wang, R | 1 |
Pandya, CD; Pillai, A | 1 |
Hajós, M; Hoffmann, WE; Kiss, T | 1 |
Eda, T; Iwakura, Y; Kato, T; Mizuno, M; Nawa, H; Shibuya, M; Takasu, Y; Zheng, Y | 1 |
Besterman, AD; Harrison, PJ; Huang, W; Hyde, TM; Kleinman, JE; Law, AJ; Lipska, BK; O'Donnell, P; Papaleo, F; Piantadosi, P; Sei, Y; Straub, RE; Thomas, CJ; Vakkalanka, R; Wang, Y; Weinberger, DR | 1 |
Gil, C; Lipina, TV; Martinez, A; Palomo, V; Roder, JC | 1 |
Rico, B | 1 |
Chappie, TA; Humphrey, JM; Menniti, FS; Schmidt, CJ | 1 |
Jahnke, U | 1 |
Hommer, DW; Pickar, D; van Kammen, DP; Zahn, TP | 1 |
1 review(s) available for quinazolines and Dementia Praecox
Article | Year |
---|---|
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Topics: Corpus Striatum; Humans; Models, Biological; Molecular Structure; Papaverine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Quinazolines; Schizophrenia; Signal Transduction | 2007 |
2 trial(s) available for quinazolines and Dementia Praecox
Article | Year |
---|---|
Examining the effects of the histone methyltransferase inhibitor BIX-01294 on histone modifications and gene expression in both a clinical population and mouse models.
Topics: Animals; Azepines; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Enzyme Inhibitors; Female; Gene Expression Regulation; Histone Code; Histone Methyltransferases; Histones; Humans; Kruppel-Like Factor 4; Leukocytes, Mononuclear; Male; Mice; Mutation; Quinazolines; Reelin Protein; RNA, Messenger; Schizophrenia | 2019 |
Prazosin, a specific alpha 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adult; Arousal; Autonomic Nervous System; Clinical Trials as Topic; Double-Blind Method; Female; Galvanic Skin Response; Humans; Male; Prazosin; Quinazolines; Schizophrenia | 1984 |
8 other study(ies) available for quinazolines and Dementia Praecox
Article | Year |
---|---|
ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Male; Motor Activity; Quinazolines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Schizophrenic Psychology | 2013 |
TrkB interacts with ErbB4 and regulates NRG1-induced NR2B phosphorylation in cortical neurons before synaptogenesis.
Topics: Animals; Antibodies, Neutralizing; Carbazoles; Cerebral Cortex; Enzyme Inhibitors; Female; Humans; Indole Alkaloids; Mice; Mice, Knockout; Neuregulin-1; Neurons; Phospholipase C gamma; Phosphorylation; Quinazolines; Receptor, ErbB-4; Receptor, trkB; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Signal Transduction; Synapses; Tyrphostins | 2014 |
Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia.
Topics: Animals; Biphenyl Compounds; Delta Rhythm; Disease Models, Animal; Dizocilpine Maleate; Electric Stimulation; Electroencephalography; Excitatory Postsynaptic Potentials; Hippocampus; Lidocaine; Male; N-Methylaspartate; Neuronal Plasticity; Prefrontal Cortex; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Sulfonamides; Synaptic Transmission; Time Factors | 2011 |
Antipsychotic potential of quinazoline ErbB1 inhibitors in a schizophrenia model established with neonatal hippocampal lesioning.
Topics: Animals; Antipsychotic Agents; Behavior; Conditioning, Classical; ErbB Receptors; Genes, erbB-1; Hippocampus; Infusions, Intraventricular; Male; Motor Activity; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Schizophrenia; Signal Transduction | 2010 |
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy.
Topics: Adenine; Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; B-Lymphocytes; Blotting, Western; Cell Line, Transformed; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Flow Cytometry; Genetic Association Studies; Humans; Mice; Molecular Structure; Neuregulin-1; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptor, ErbB-4; Reverse Transcriptase Polymerase Chain Reaction; Schizophrenia; Signal Transduction | 2012 |
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 7; Dose-Response Relationship, Drug; Drugs, Investigational; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Male; Memory; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Neural Inhibition; Nootropic Agents; Phosphodiesterase Inhibitors; Quinazolines; Schizophrenia; Spatial Behavior; Triazoles | 2013 |
Finding a druggable target for schizophrenia.
Topics: Adenine; Animals; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Humans; Neuregulin-1; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-4; Schizophrenia; Signal Transduction | 2012 |
Experimental pharmacotherapeutics for schizophrenia and addiction.
Topics: D-Amino-Acid Oxidase; Drugs, Investigational; Humans; Molecular Structure; Nitriles; Quinazolines; Schizophrenia; Substance-Related Disorders; Tetrahydroisoquinolines | 2008 |